Edgewise Therapeutics appoints Christopher Martin to Board of Directors

Edgewise Therapeutics, Inc.

Martin, former CCO of Verona Pharma (acquired by Merck for ~$10B), joins as Class I director.
Appointment effective November 19, 2025; term expires at 2028 annual meeting.
Receives $40k annual cash retainer and ~$700k stock option grant (monthly vest over 3 years).
Board cites Martin's commercial launch expertise as critical for Becker MD launch and CV Phase 3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.